HopkinsCFAR
@hopkinscfar.bsky.social
Aim: To enhance the integration and productivity of JHU HIV/AIDS research by promoting inter-disciplinary innovation and collaboration for creating synergy and efficiencies across disciplines, divisions and partner institutions
www.hopkinscfar.org
www.hopkinscfar.org
Both regimens of HepB-CpG vaccine achieved a superior seroprotection response compared with 3 doses of HepB-alum vaccine, potentially offering PWH better protection against HBV infection
July 23, 2025 at 2:19 PM
Both regimens of HepB-CpG vaccine achieved a superior seroprotection response compared with 3 doses of HepB-alum vaccine, potentially offering PWH better protection against HBV infection
In a phase 3 clinical trial, PWH with nonresponse to prior hepatitis B vaccination were randomly assigned to receive 2 doses of HepB-CpG vaccine or 3 doses of HepB-alum vaccine of HepB-alum vaccine.
July 23, 2025 at 2:19 PM
In a phase 3 clinical trial, PWH with nonresponse to prior hepatitis B vaccination were randomly assigned to receive 2 doses of HepB-CpG vaccine or 3 doses of HepB-alum vaccine of HepB-alum vaccine.
Nonresponse to hepatitis B vaccine is common among people with HIV (PWH), resulting in hepatitis B virus (HBV) vulnerability.
July 23, 2025 at 2:18 PM
Nonresponse to hepatitis B vaccine is common among people with HIV (PWH), resulting in hepatitis B virus (HBV) vulnerability.